Clinical risk management of herb-drug interactions

British Journal of Clinical Pharmacology

Volumn 63, Issue 3, 2007, Pages 258-267

  De Smet, Peter A G M ^a,b  

^a Scientific Institute Dutch Pharmacists   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Herb drug interactions; Risk management

Indexed keywords

ANTICOAGULANT AGENT; ATORVASTATIN; CYTOCHROME P450; FLUINDOSTATIN; FLUOXETINE; GLYCOPROTEIN P; HERBACEOUS AGENT; HYPERICUM PERFORATUM EXTRACT; MEFLOQUINE; MEVINOLIN; NELFINAVIR; NIFEDIPINE; QUINIDINE; QUININE; RITONAVIR; SAQUINAVIR; VERAPAMIL;

ALTERNATIVE MEDICINE; CODING; DEPRESSION; DRUG SURVEILLANCE PROGRAM; FOOD DRUG INTERACTION; GARLIC; HERB DRUG INTERACTION; HUMAN; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; RISK REDUCTION;

HERB-DRUG INTERACTIONS; HUMANS; PHYTOTHERAPY; PLANT PREPARATIONS; RISK FACTORS;

EID: 33846991638     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02797.x     Document Type: Review

References (69)

1. Harrison RA, Holt D, Pattison DJ, Elton PJ. Who and how many people are taking herbal supplements? A survey of 21,923 adults. Int J Vitam Nutr Res 2004; 74: 183-6.
2. Brownie S, Rolfe M. Health characteristics of older Australian dietary supplement users compared to non-supplement users. Asia Pac J Clin Nutr 2004; 13: 365-71.
3. Peng CC, Glassman PA, Trilli LE, Hayes-Hunter J, Good CB. Incidence and severity of potential drug-dietary supplement interactions in primary care patients: an exploratory study of 2 outpatient practices. Arch Intern Med 2004; 164: 630-6.
4. Bruno JJ, Ellis JJ. Herbal use among US elderly: 2002 National Health Interview Survey. Ann Pharmacother 2005; 39: 643-8.
5. Hu Z, Yang X, Ho PC, Chan SY, Heng PW, Chan E, Duan W, Koh HL, Zhou S. Herb-drug interactions: a literature review. Drugs 2005; 65: 1239-82.
6. Mills E, Wu P, Johnston BC, Gallicano K, Clarke M, Guyatt G. Natural health product-drug interactions: a systematic review of clinical trials. Ther Drug Monit 2005; 27: 549-57.
7. Chavez ML, Jordan MA, Chavez PI. Evidence-based drug-herbal interactions. Life Sci 2006; 78: 2146-57.
8. Misson JC. A review of clinical risk management. J Qual Clin Pract 2001; 21: 131-4.
9. Madar J. Clinical risk management in newborn and neonatal resuscitation. Semin Fetal Neonatal Med 2005; 10: 45-61.
10. Sandars J. The theory and evidence base for clinical risk management. In: Clinical Risk Management in Primary Care, eds Haynes K, Thomas M. Abingdon: Radcliffe Publishing 2005: 45-59.
11. Andrews E, Gilsenan A, Cook S. Therapeutic risk management interventions: feasibility and effectiveness. J Am Pharm Assoc (Wash DC) 2004; 44: 491-500.
12. Committee for Medicinal Products for Human Use. Guideline on Risk Management Systems for Medicinal Products for Human Use. 2005. Doc. Ref. EMEA/CHMP/96268/2005. Available at http://www.emea.eu.int/pdfs/human/euleg/ 9626805en.pdf (last accessed: 28 December 2005).
13. Barnes J. Pharmacovigilance of herbal medicines: a UK perspective. Drug Saf 2003; 26: 829-51.
14. De Smet PAGM. An introduction to herbal pharmacovigilance. In: Adverse Effects of Herbal Drugs, Vol. 3, eds De Smet PAGM, Keller K, Hänsel R, Chandler RF. Berlin: Springer-Verlag 1997: 1-13.
15. De Smet PAGM. Herbal medicine in Europe - relaxing regulatory standards. N Engl J Med 2005; 352: 1176-8.
16. Fugh-Berman A, Ernst E. Herb-drug interactions: review and assessment of report reliability. Br J Clin Pharmacol 2001; 52: 587-95.
17. De Smet PAGM. The interference of botanicals and nutraceuticals with the effects of antithrombotic agents: how should the available evidence be weighed? Thromb Res 2005; 117: 19-24.
18. Barnes J, Abbot NC. Experiences with complementary remedies: a survey of community pharmacists. Pharm J 1999; 263: R37.
19. MacPherson H, Liu B. The safety of Chinese herbal medicine: a pilot study for a national survey. J Altern Complement Med 2005; 11: 617-26.
20. Anonymous. Statutory Regulation of Herbal Medicine and Acupuncture - Report on the Consultation. 2005. London: Department of Health. Available at http://www.dh.gov.uk/assetRoot/04/10/32/69/04103269.pdf (last accessed: 4 February 2006).
21. Barnes J, Mills SY, Abbot NC, Willoughby M, Ernst E. Different standards for reporting ADRs to herbal remedies and conventional OTC medicines: face-to-face interviews with 515 users of herbal remedies. Br J Clin Pharmacol 1998; 45: 496-500.
22. Zhou S, Gao Y, Jiang W, Huang M, Xu A, Paxton JW. Interactions of herbs with cytochrome P450. Drug Metab Rev 2003; 35: 35-98.
23. Zhou S, Lim LY, Chowbay B. Herbal modulation of P-glycoprotein. Drug Metab Rev 2004; 36: 57-104.
24. Zhou S, Chan E, Li SC, Huang M, Chen X, Li X, Zhang Q, Paxton JW. Predicting pharmacokinetic herb-drug interactions. Drug Metabol Drug Interact 2004; 20: 143-58.
25. Zhou S, Huang M, Xu A, Yang H, Duan W, Paxton JW. Prediction of herb-drug metabolic interactions: a simulation study. Phytother Res 2005; 19: 464-71.
26. Merlo J, Liedholm H, Lindblad U, Bjorck-Linne A, Falt J, Lindberg G, Melander A. Prescriptions with potential drug interactions dispensed at Swedish pharmacies in January 1999: cross sectional study. BMJ 2001; 323: 427-8.
27. van Roon EN, Flikweert S, le Comte M, Langendijk PN, Kwee-Zuiderwijk WJ, Smits P, Brouwers JRBJ. Clinical relevance of drug-drug interactions: a structured assessment procedure. Drug Saf 2005; 28: 1131-9.
28. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165: 1095-106.
29. Markowitz JS, DeVane CL, Boulton DW, Carson SW, Nahas Z, Risch SC. Effect of St. John's wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. Life Sci 2000; 66: L133-L139.
30. De Smet PAGM. Health risks of herbal remedies: an update. Clin Pharmacol Ther 2004; 76: 1-17.
31. Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement. Ann Intern Med 2006; 144: 364-7.
32. Stricker BH, Psaty BM. Detection, verification, and quantification of adverse drug reactions. BMJ 2004; 329: 44-7.
33. Kaboli PJ, McClimon BJ, Hoth AB, Barnett MJ. Assessing the accuracy of computerized medication histories. Am J Manag Care 2004; 10: 872-7.
34. Wallerstedt SM, Skrtic S. Bruk av naturläkemedel dokumenteras sällan i journalen. Risk att interaktioner och biverkningar missas, visar punktprevalensstudie. Lakartidningen 2005; 102: 3220-2.
35. Brinker F. Herb Contraindications and Drug Interactions, 3rd edn. Sandy: Eclectic Medical Publications 2001.
36. van Roon EN, Langendijk PN, Flikweert S, Smits P, Kwee-Zuiderwijk WJ, le Comte M, Brouwers JRBJ. Wikken en wegen. Gestructureerde beoordeling van geneesmiddelinteracties. Pharm Weekbl 2003; 138: 850-5.
37. Buurma H, De Smet PA, Leufkens HG, Egberts AC. Evaluation of the clinical value of pharmacists' modifications of prescription errors. Br J Clin Pharmacol 2004; 58: 503-11.
38. Markowitz JS, Donovan JL, DeVane CL, Taylor RM, Ruan Y, Wang JS, Chavin KD. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003; 290: 1500-4.
39. Zhou S, Chan E, Pan SQ, Huang M, Lee EJ. Pharmacokinetic interactions of drugs with St John's wort. J Psychopharmacol 2004; 18: 262-76.
40. Rochat B. Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism. Clin Pharmacokinet 2005; 44: 349-66.
41. Anonymous. Drug Interactions - Cytochrome P450 System - Abbreviated Clinical Table. 2006. Indianapolis: Department of Medicine, Indiana University School of Medicine. Available at http://medicine.iupui.edu/flockhart/clinlist. htm (last accessed: 3 February 2006).
42. Anonymous. British National Formulary no. 50 - Appendix 1 Interactions - List of drug interactions - Antidepressants - St John's Wort. 2005. London: British Medical Association and Royal Pharmaceutical Society. Available at http://www.bnf.org/bnf/bnf/current/noframes/41001i905.htm (last accessed: 5 February 2006).
43. De Gier JJ. Commentaren Medicatiebewaking 2005/2006. Houten: Health Base 2005.
44. Anonymous. Kombirom.nl. 2006. Maarssen: ID/farma. Available at https://www.kombirom.nl/startpagina.asp? (last accessed: 3 February 2006).
45. Piscitelli SC, Burstein AH, Welden N, Gallicano KD, Falloon J. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 2002; 34: 234-8.
46. Spence JD. Drug interactions with grapefruit: whose responsibility is it to warn the public? Clin Pharmacol Ther 1997; 61: 395-400.
47. Nooijens H, Noort M. Medicatiebewaking van zelfzorg geïntroduceerd met nieuw project. Pharm Weekbl 1998; 133: 1664-5.
48. Anonymous. Unlicensed Herbal Remedies Made Up to Meet the Need of Individual Patients. Section 12(1) of the Medicines Act 1968. 2006. London: Medicines and Healthcare Products Regulatory Agency. Available at http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&nodeId=659 (last accessed: 5 February 2006).
49. Weideman RA, Bernstein IH, McKinney WP. Pharmacist recognition of potential drug interactions. Am J Health Syst Pharm 1999; 56: 1524-9.
50. Halkin H, Katzir I, Kurman I, Jan J, Malkin BB. Preventing drug interactions by online prescription screening in community pharmacies and medical practices. Clin Pharmacol Ther 2001; 69: 260-5.
51. Kremens B, Brendel E, Bald M, Czyborra P, Michel MC. Loss of blood pressure control on withdrawal of fluconazole during nifedipine therapy. Br J Clin Pharmacol 1999; 47: 707-8.
52. De Smet PAGM, Touw DJ. Safety of St John's wort (Hypericum perforatum). Lancet 2000; 355: 575-6.
53. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, Ang CY. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging 2005; 22: 525-39.
54. Andersen V, Pedersen N, Larsen NE, Sonne J, Larsen S. Intestinal first pass metabolism of midazolam in liver cirrhosis - effect of grapefruit juice. Br J Clin Pharmacol 2002; 54: 120-4.
55. Yin OQ, Tomlinson B, Waye MM, Chow AH, Chow MS. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics 2004; 14: 841-50.
56. Anonymous. Legal Status and Reclassification. 2006. London: Medicines and Healthcare Products Regulatory Agency. Available at http://www.mhra.gov.uk/ home/idcplg?IdcService=SS_GET_PAGE&nodeId=107 (last accessed: 5 February 2006).
57. Mai I, Bauer S, Perloff ES, Johne A, Uehleke B, Frank B, Budde K, Roots I. Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction. Clin Pharmacol Ther 2004; 76: 330-40.
58. Arold G, Donath F, Maurer A, Diefenbach K, Bauer S, Henneicke-von Zepelin HH, Friede M, Roots I. No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's wort extract. Planta Med 2005; 71: 331-7.
59. De Smet PAGM. Drug therapy: herbal remedies. N Engl J Med 2002; 347: 2046-56.
60. Britten N, Jenkins L, Barber N, Bradley C, Stevenson F. Developing a measure for the appropriateness of prescribing in general practice. Qual Saf Health Care 2003; 12: 246-50.
61. Barber N, Bradley C, Barry C, Stevenson F, Britten N, Jenkins L. Measuring the appropriateness of prescribing in primary care: are current measures complete? J Clin Pharm Ther 2005; 30: 533-9.
62. Williams SE, Bond CM, Menzies C. A pharmaceutical needs assessment in a primary care setting. Br J Gen Pract 2000; 50: 95-9.
63. Pound P, Britten N, Morgan M, Yardley L, Pope C, Daker-White G, Campbell R. Resisting medicines: a synthesis of qualitative studies of medicine taking. Soc Sci Med 2005; 61: 133-55.
64. Thornton H. Patients' understanding of risk. BMJ 2003; 327: 693-4.
65. Godolphin W. The role of risk communication in shared decision making. BMJ, 2003; 327: 692-3.
66. Anonymous. Staat van de Gezondheidszorg 2004: Patiëntveiligheid - De Toepassing van Geneesmiddelen en Medische Hulpmiddelen in Zorginstellingen en Thuis. Den Haag: Inspectie voor de Gezondheidszorg, Staatstoezicht op de Volksgezondheid 2004.
67. Becker ML, Kallewaard M, Caspers PW, Schalekamp T, Stricker BH. Potential determinants of drug-drug interaction associated dispensing in community pharmacies. Drug Saf 2005; 28: 371-8.
68. Buurma H, De Smet PAGM, Egberts ACG. Clinical risk management in Dutch community pharmacies: the case of drug-drug interactions. Drug Saf 2006; 29: 723-32.
69. Bessell TL, Anderson JN, Silagy CA, Sansom LN, Hiller JE. Surfing, self-medicating and safety: buying non-prescription and complementary medicines via the internet. Qual Saf Health Care 2003; 12: 88-92.